Diffusion Pharmaceuticals Completes Phase 1b Study of TSC in Hospitalized COVID-19 Patients
February 16, 2021 07:35 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
Diffusion Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $30 Million
February 11, 2021 22:02 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative clinical stage biopharmaceutical company...
Diffusion Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock
February 11, 2021 17:54 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative clinical stage biopharmaceutical company...
Diffusion Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Conference
January 11, 2021 07:30 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced that the Company is participating in the...
Diffusion Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Updates
November 12, 2020 16:02 ET
|
Diffusion Pharmaceuticals Inc.
Initiated and Advanced Clinical Trial Evaluating Lead Product Candidate in COVID-19 Patients Announces Next Steps in Development Program for Lead Product Candidate Ended Quarter with $21.9...
Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer
October 19, 2020 08:00 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced the appointment of Christopher D. Galloway, M.D....
Diffusion Pharmaceuticals Strengthens Management Team with Appointment of William Elder as General Counsel and Corporate Secretary
September 24, 2020 08:00 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”) today announced the appointment of William Elder, J.D., to the...
Diffusion Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Virtual Global Investment Conference
September 11, 2020 08:30 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced its management will present at the H.C....
Diffusion Pharmaceuticals Doses First Two Patients with TSC in COVID-19 Clinical Trial
September 10, 2020 08:00 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”) today announced dosing of the first two patients in the...
Diffusion Pharmaceuticals Names Director Dr. Robert Cobuzzi as President and Chief Executive Officer
September 08, 2020 16:02 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced that Robert (“Bob”) J. Cobuzzi Jr., Ph.D., who...